Pipeline

A diversified pipeline of improved medicines

Pipeline

A diversified pipeline of improved medicines

We take a strategic approach to pipeline selection and manage
all proprietary programs in-house.

Kashiv BioSciences has an in-depth, multi-tiered selection process for evaluating drug candidates to meet our high standards for product selection and development.

1. The process starts with data mining to identify sub-optimal products.

2. We next conduct extensive secondary market research to evaluate clinical unmet need, technical feasibility, market potential, intellectual property, and the competitive landscape.

3. We then develop and validate the selected target product profiles via interviews and market surveys with doctors, payers, and caregivers.

4. As a final step, we develop a compelling business case validated by market potential, development cost, exclusivity, and profitability.

Kashiv-Pipeline-3

505(b)(2)

Currently with several development products targeting unmet clinical needs, our growing 505(b)(2) pipeline aims to get the highest standard of medication to people faster.

pipeline-505b

*Orphan Disease

pipeline-505b

*Orphan Diseases

Biosimilars

Kashiv is advancing a pipeline of complex proteins and monoclonal antibodies with lead candidates in oncology and immunology.

PIPELINE-biosimilar-2
PIPELINE-biosimilar-2

Prodrugs

We are discovering and developing prodrugs with optimized properties that address major unmet patient and market needs.

PIPELINE-prodrugs
PIPELINE-prodrugs